C. Burty

发表

Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The “Mortalité 2000 and 2005” Surveys (ANRS EN19 and Mortavic)

P. Morlat, D. Costagliola, C. Lewden, 2008, Journal of acquired immune deficiency syndromes.

Relevance of fluoroquinolone use in hospitals in the Lorraine region of France before and after corrective measures: An investigation by the Antibiolor network

T. Doco‐Lecompte, B. Demoré, C. Rabaud, 2012, Scandinavian journal of infectious diseases.

Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study.

P. Morlat, D. Costagliola, C. Lewden, 2009, Journal of hepatology.

Liver‐related deaths in HIV‐infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalité 2005 survey, ANRS EN19) *

P. Morlat, D. Costagliola, C. Lewden, 2009, HIV medicine.

[Relevance of fluoroquinolone use in Lorraine: results of the first survey].

T. Doco‐Lecompte, B. Demoré, C. Rabaud, 2010, Medecine et maladies infectieuses.

Occult hepatitis B infection in patients infected with HIV: Report of two cases of hepatitis B reactivation and prevalence in a hospital cohort

C. Rabaud, V. Venard, H. Jeulin, 2010, Journal of medical virology.

Tolerability of fosamprenavir/ritonavir associated with zidovudine-lamivudine used as postexposure prophylaxis for HIV infection.

Y. Yazdanpanah, K. Ghomari, B. Christian, 2008, Journal of acquired immune deficiency syndromes.

Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.

B. Christian, C. Rabaud, I. Béguinot, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Severe Strongyloidiasis in AIDS: Is Steroid Therapy Guilty Again?

Y. Yazdanpanah, K. Ghomari, B. Christian, 2008 .

Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey.

P. Morlat, D. Costagliola, C. Lewden, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Tolerability of two different combinations of antiretroviral drugs including tenofovir used in occupational and nonoccupational postexposure prophylaxis for HIV.

Y. Yazdanpanah, B. Christian, C. Rabaud, 2010, AIDS patient care and STDs.

Relevance of fluoroquinolone use in a French teaching hospital.

T. Doco‐Lecompte, B. Demoré, C. Rabaud, 2012, Medecine et maladies infectieuses.

P643 Causes of liver related death in HIV-infected patients in France: mortality 2005 Survey

P. Morlat, D. Costagliola, C. Lewden, 2007 .

Severe liver toxicity in postexposure prophylaxis for HIV infection with a zidovudine, lamivudine and fosamprenavir/ritonavir regimen.

Y. Yazdanpanah, C. Rabaud, Y. Mouton, 2007, AIDS.

Antibiolor, the Lorraine antibiology network: update on 7 years of activity.

T. Doco‐Lecompte, C. Burty, J. Birgé, 2012, Medecine et maladies infectieuses.

HIV postexposure prophylaxis: new guidelines

C. Rabaud, E. Bouvet, D. Abiteboul, 2007 .

Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial

C. Katlama, M. Shoai, H. Melliez, 2018, The Journal of antimicrobial chemotherapy.

[Impact of corrective measures on fluoroquinolones prescriptions for urinary tract infections during a 2-round relevance study].

S. Hénard, V. Gendrin, L. Letranchant, 2012, Presse medicale.